SG11201901672RA - Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan - Google Patents
Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetanInfo
- Publication number
- SG11201901672RA SG11201901672RA SG11201901672RA SG11201901672RA SG11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lilotomab
- pct
- arm
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16189191 | 2016-09-16 | ||
| EP17164164 | 2017-03-31 | ||
| EP17170641 | 2017-05-11 | ||
| EP17175768 | 2017-06-13 | ||
| PCT/EP2017/073336 WO2018050851A1 (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901672RA true SG11201901672RA (en) | 2019-03-28 |
Family
ID=59895313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901672RA SG11201901672RA (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
| SG10202102588QA SG10202102588QA (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102588QA SG10202102588QA (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190192703A1 (enExample) |
| EP (1) | EP3512881A1 (enExample) |
| JP (1) | JP2019529433A (enExample) |
| KR (1) | KR20190054113A (enExample) |
| CN (1) | CN109790219A (enExample) |
| AU (1) | AU2017327772A1 (enExample) |
| BR (1) | BR112019004838A2 (enExample) |
| CA (1) | CA3035268A1 (enExample) |
| IL (1) | IL265387A (enExample) |
| MX (1) | MX2019003029A (enExample) |
| PH (1) | PH12019550033A1 (enExample) |
| RU (1) | RU2019110955A (enExample) |
| SG (2) | SG11201901672RA (enExample) |
| WO (1) | WO2018050851A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110997670B (zh) * | 2017-08-04 | 2022-11-01 | 百时美施贵宝公司 | [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物 |
| CN111372613A (zh) * | 2017-11-22 | 2020-07-03 | 诺帝克纳诺维科特公司 | 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤 |
| KR20240083769A (ko) | 2022-12-05 | 2024-06-12 | 김원석 | 휴대할 수 있는 해수 정화 유닛용 물통 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001010462A1 (en) * | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| EP3272364B1 (en) * | 2011-12-13 | 2020-07-29 | Nordic Nanovector ASA | Chimeric therapeutic anti-cd37 antibodie hh1 |
| EP3262166A4 (en) * | 2015-02-24 | 2018-08-15 | The Regents of The University of California | Binding-triggered transcriptional switches and methods of use thereof |
-
2017
- 2017-09-15 SG SG11201901672RA patent/SG11201901672RA/en unknown
- 2017-09-15 JP JP2019515291A patent/JP2019529433A/ja active Pending
- 2017-09-15 MX MX2019003029A patent/MX2019003029A/es unknown
- 2017-09-15 BR BR112019004838A patent/BR112019004838A2/pt not_active IP Right Cessation
- 2017-09-15 US US16/329,661 patent/US20190192703A1/en not_active Abandoned
- 2017-09-15 AU AU2017327772A patent/AU2017327772A1/en not_active Abandoned
- 2017-09-15 WO PCT/EP2017/073336 patent/WO2018050851A1/en not_active Ceased
- 2017-09-15 KR KR1020197010585A patent/KR20190054113A/ko not_active Ceased
- 2017-09-15 CN CN201780055437.7A patent/CN109790219A/zh active Pending
- 2017-09-15 SG SG10202102588QA patent/SG10202102588QA/en unknown
- 2017-09-15 RU RU2019110955A patent/RU2019110955A/ru unknown
- 2017-09-15 CA CA3035268A patent/CA3035268A1/en active Pending
- 2017-09-15 EP EP17768448.7A patent/EP3512881A1/en not_active Withdrawn
-
2019
- 2019-03-07 PH PH12019550033A patent/PH12019550033A1/en unknown
- 2019-03-14 IL IL265387A patent/IL265387A/en unknown
-
2021
- 2021-06-22 US US17/304,541 patent/US20220160907A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019003029A (es) | 2019-09-13 |
| KR20190054113A (ko) | 2019-05-21 |
| JP2019529433A (ja) | 2019-10-17 |
| RU2019110955A3 (enExample) | 2020-11-26 |
| EP3512881A1 (en) | 2019-07-24 |
| RU2019110955A (ru) | 2020-10-20 |
| US20220160907A1 (en) | 2022-05-26 |
| PH12019550033A1 (en) | 2019-07-29 |
| CN109790219A (zh) | 2019-05-21 |
| US20190192703A1 (en) | 2019-06-27 |
| WO2018050851A1 (en) | 2018-03-22 |
| BR112019004838A2 (pt) | 2019-06-04 |
| CA3035268A1 (en) | 2018-03-22 |
| AU2017327772A1 (en) | 2019-03-21 |
| SG10202102588QA (en) | 2021-04-29 |
| IL265387A (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201903236SA (en) | Lasofoxifene treatment of er+ breast cancer | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells |